

## Evonik Financials & ESG KPIs

---

Financial KPIs Group	P. 2
ESG KPIs Group	P. 3
Segment KPIs	P. 4-6
Group Income Statement	P. 7-8
Group Balance Sheet	P. 9
Group Cash Flow Statement	P. 10
Group Net Financial Position	P. 11
Definitions	P. 12

As of Q3 2025 (published November 4, 2025)

**Evonik Group Financials**

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3
External Sales	12,199	14,955	18,488	15,267	3,796	3,930	3,832	3,599	15,157	3,777	3,499	3,391
<i>Growth (%)</i>	-7%	23%	24%	-17%	-5%	1%	2%	0%	-1%	-1%	-11%	-12%
<i>Volumes (%)</i>	-3%	11%	-4%	-8%	4%	5%	5%	4%	4%	2%	-4%	-6%
<i>Prices (%)</i>	-3%	12%	18%	-3%	-5%	-2%	0%	-2%	-2%	-2%	-1%	-1%
<i>Exchange Rates (%)</i>	-2%	-2%	5%	-2%	-1%	0%	-2%	0%	-1%	1%	-3%	-3%
<i>Other (incl. M&amp;A; %)</i>	1%	2%	5%	-4%	-3%	-2%	-1%	-2%	-2%	-2%	-3%	-2%
Adjusted EBITDA	1,906	2,383	2,490	1,656	522	578	577	388	2,065	560	509	448
<i>Margin (%)</i>	15.6%	15.9%	13.5%	10.8%	13.8%	14.7%	15.1%	10.8%	13.6%	14.8%	14.5%	13.2%
EBIT	819	1,173	942	-243	252	93	322	-91	577	299	236	-25
Adjusted EBIT	890	1,338	1,350	521	266	329	322	111	1,027	309	250	197
<i>Margin (%)</i>	7.3%	8.9%	7.3%	3.4%	7.0%	8.4%	8.4%	3.1%	6.8%	8.2%	7.1%	5.8%
Adjusted EPS	1.37	2.12	2.26	0.79	0.42	0.50	0.58	0.16	1.67	0.59	0.34	0.27
Free Cash Flow	780	950	785	801	127	217	357	172	873	195	-211	300
Cash Conversion Rate <sup>1</sup>	41%	40%	32%	48%					42%			
Capex (Cash outflow for investment in intangible assets, pp&e)	956	865	865	793	251	143	180	266	840	190	176	181
Capital employed (annual average)	14,600	14,799	16,192	15,406					14,493			
ROCE (%)	6.1%	9.0%	8.3%	3.4%					7.1%			
Dividend (€)	1.15	1.17	1.17	1.17					1.17			
Employees (continuing operations)	33,106	33,004	34,029	33,409	33,090	32,757	32,040	31,930	31,930	31,585	31,273	31,297

<sup>1</sup> Free cash flow conversion = FCF / adj. EBITDA

## Evonik Group Environment, Social & Governance KPIs

Full set of ESG KPIs published separately on our IR website: [evonik.finance/investor-relations](https://evonik.finance/investor-relations)

	2020 FY	2021 FY	2022 FY	2023 FY	2024 FY
<b>Strategy &amp; Growth</b>					
Sales share with "Next Generation Solutions"	37%	41%	43%	43%	45%
<b>Governance &amp; Compliance</b>					
Training rate fighting money laundering	82%	96%	97%	98%	99%
Training rate antitrust law	88%	83%	85%	89%	90%
Training rate fighting corruption	88%	92%	91%	86%	95%
Training rate code of conduct	89%	89%	89%	92%	96%
Training rate Human Rights (new in 2024)				90%	84%
<b>Value Chain &amp; Products</b>					
Procurement volume (in € billion)	8.0	10.4	13.6	11.3	10.5
Production output (million metric tons)	8.9	9.5	8.4	7.5	7.3
Use of renewable raw materials in production	8.5%	9.7%	11.1%	12.0%	9.0%
Raw material suppliers covered by TfS assessments	73%	69%	66%	67%	71%
No. of sustainability audits (Evonik/TfS)	258	284	378	492	596
No. of sustainability assessments (Evonik/TfS)	1,148	1,345	1,545	1,296	1,309
R&D expenses (€ million)	433	464	461	443	459
<b>The environment</b>					
Scope 1 greenhouse gas emissions (thousands metric tons CO <sub>2</sub> )	4,860	4,381 <sup>a</sup>	4,221 <sup>a</sup>	3890 <sup>b</sup>	3,390
Scope 2 greenhouse gas emissions (thousands metric tons CO <sub>2</sub> )	571 <sup>b</sup>	1,916 <sup>a</sup>	1,757 <sup>a</sup>	1400 <sup>b</sup>	1,670
Scope 3 greenhouse gas emissions (million metric tons CO <sub>2</sub> )	20.0 <sup>b</sup>	23.4	20.5 <sup>a</sup>	18.9 <sup>b</sup>	21.6
% Reduction in greenhouse gas emissions Scope 1 & 2 (million metric tons CO <sub>2</sub> ) vs base year	-43	-43	-5 <sup>c</sup>	-15 <sup>c</sup>	-20
Total water intake (in million m <sup>3</sup> )	561.4	462 <sup>d</sup>	444 <sup>d</sup>	403	431
Specific water intake (in m <sup>3</sup> freshwater / metric ton production)	36.5	26.8 <sup>d</sup>	29.5 <sup>d</sup>	29.9	32.2
Production waste (thousand metric tons)	311	342 <sup>d</sup>	335 <sup>d</sup>	287	306
Specific production waste (in ton of waster per metric ton production)		0.036	0.04	0.038	0.042
<b>Employees</b>					
Early employee turnover	1.3%	2.2%	1.9%	2.2%	1.7%
Continuing professional development per employee (hours)	12	5	4	4	2
Women at level "Executives" (circle 1)	15.9%	17.7%	20.3%	22.2%	21.8%
Women at level "Senior management" (circle 2)	14.2%	17.6%	17.1%	18.5%	19.1%
Women in management (circle 3)	27.1%	28.7%	29.9%	30.3%	31.4%
Women in management (circles 1-3)	26.1%	27.9%	29.1%	29.6%	30.7%
<b>Safety</b>					
Occupational health performance index	5.4	5.6	5.5	5.5	5.5
Accident frequency rate (no. of accidents / working hours) <sup>b</sup>	0.16	0.19	0.25	0.21	0.14
Incident frequency rate (no. of accidents / working hours) <sup>b</sup>	1.45	0.48	0.49	0.43	0.44

a: adjusted figures corresponding to GHG Protocol Standards | b: Correction of data based on methodological improvements | c: for new target period 2021-2030 | d: data corrected for fast-close process

(for ESG KPI definitions please see separate "Definitions" page at the end of the file)

**Custom Solutions**

in € million	2020	2021	2022	2023	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3
Sales	4,483	5,357	6,568	5,608	1,392	1,472	1,465	1,408	5,737	1,427	1,367	1,340
Growth (% yoy)	-3%	19%	23%	-15%	-3%	3%	4%	3%	2%	3%	-7%	-9%
Volumes (%)	-1%	14%	-3%	-11%	3%	8%	6%	5%	5%	2%	-5%	-8%
Prices (%)	0%	5%	13%	1%	-5%	-3%	0%	-2%	-2%	0%	1%	1%
Exchange Rates (%)	-2%	-1%	5%	-3%	-1%	-1%	-2%	0%	-1%	1%	-3%	-3%
Other (incl. M&A; %)	0%	1%	8%	-2%	0%	-1%	0%	0%	0%	0%	0%	1%
Sales Additives	2,965	3,588	4,523	3,747	975	1,017	980	935	3,908	974	942	899
Volumes (%)	-	+	-	-	+	+	+	+	+	=	-	-
Prices (%)	=	+	+	=	-	-	=	=	-	=	=	=
Sales Care	1,518	1,768	2,045	1,861	417	455	485	473	1,829	453	425	441
Volumes (%)	+	+	=	-	-	=	+	=	=	+	-	-
Prices (%)	=	+	+	+	=	=	=	-	=	=	=	+
Adjusted EBITDA	942	1,086	1,162	852	231	281	287	179	978	256	254	215
Margin (%)	21.0%	20.3%	17.7%	15.2%	16.6%	19.1%	19.6%	12.7%	17.0%	17.9%	18.6%	16.0%
EBITDA yoy Additives	-	+	+	-	+	+	+	+	+	+	-	-
EBITDA yoy Care	=	+	+	-	+	+	-	-	-	+	-	-
EBIT					155	205	223	-25	558	170	189	120
Adjusted EBIT					156	205	210	92	663	181	180	140
Capital expenditures					49	59	71	132	311	50	78	72
Approx. Operating FCF					86	146	172	196	600	44	112	172
Capital employed (annual average)									7,524			
ROCE (%)									8.8%			
Employees						9,786	9,786		9,736		9,649	9,644

2019-2023 figures pro-forma (unaudited)

Approx. Operating FCF provided as simplified indication only (unaudited). Calculated as adj. EBITDA, plus/minus NWC change, minus capex. Not including taxes, provisions and other items, thus not adding up to Group FCF.

For sales (volume and price) and EBITDA trends yoy ("+" or "-" in case of >2% deviation; otherwise "=")

**Advanced Technologies**

in € million	2020	2021	2022	2023	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3
Sales	4,967	5,827	7,092	5,983	1,517	1,533	1,535	1,504	6,089	1,601	1,511	1,445
Growth (% yoy)	-2%	17%	22%	-16%	-3%	2%	2%	6%	2%	6%	-1%	-6%
Volumes (%)	-4%	11%	-3%	-8%	1%	2%	2%	4%	2%	6%	1%	-2%
Prices (%)	1%	8%	20%	-4%	-4%	-1%	3%	1%	0%	-3%	-1%	-1%
Exchange Rates (%)	-3%	-2%	5%	-4%	-1%	0%	-3%	0%	-1%	1%	-4%	-3%
Other (incl. M&A; %)	4%	0%	0%	0%	1%	1%	0%	1%	1%	2%	3%	0%
Sales Organics	1,469	1,681	1,868	1,742	409	441	408	407	1,665	426	401	411
Volumes (%)	-	+	-	-	=	+	=	+	+	+	-	+
Prices (%)	=	+	+	=	-	-	-	-	-	-	=	-
Sales Inorganics	2,024	2,357	3,031	2,491	625	641	615	608	2,490	621	614	595
Volumes (%)	-	+	=	-	=	+	+	=	+	=	-	-
Prices (%)	=	+	+	=	-	-	=	=	-	=	=	=
Sales Animal Nutrition	1,474	1,789	2,193	1,750	483	451	512	489	1,934	554	496	439
Volumes (%)	=	+	-	=	+	-	+	+	=	+	+	-
Prices (%)	+	+	+	-	+	+	+	+	+	-	-	-
Adjusted EBITDA	1,047	1,233	1,207	752	275	267	296	185	1,023	291	266	202
Margin (%)	21.1%	21.2%	17.0%	12.6%	18.1%	17.4%	19.3%	12.3%	16.8%	18.2%	17.6%	14.0%
EBITDA yoy Organics	-	+	=	-	-	+	-	-	-	+	-	-
EBITDA yoy Inorganics	-	+	+	-	+	+	+	-	+	-	=	-
EBITDA yoy Animal Nutrition	+	+	-	-	+	+	+	+	+	+	+	-
EBIT					158	157	205	-3	517	183	137	65
Adjusted EBIT					159	157	186	62	565	181	150	89
Capital expenditures					80	66	77	143	367	56	82	72
Approx. Operating FCF					105	139	146	124	513	156	85	182
Capital employed (annual average)									5,686			
ROCE (%)									9.9%			
Employees						9,669	9,647		9,568		9,312	9,189

2019-2023 figures pro-forma (unaudited)

Approx. Operating FCF provided as simplified indication only (unaudited). Calculated as adj. EBITDA, plus/minus NWC change, minus capex. Not including taxes, provisions and other items, thus not adding up to Group FCF.

For sales (volume and price) and EBITDA trends yoy ("+" or "-" in case of >2% deviation; otherwise "=")

**Infrastructure (including remainder of former Performance Materials division = C4 business) / Other**

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1 <sup>1</sup>	2024 Q2 <sup>1</sup>	2024 Q3 <sup>1</sup>	2024 Q4 <sup>1</sup>	2024 FY <sup>1</sup>	2025 Q1	2025 Q2	2025 Q3
Sales Infrastructure & Other	2,747	3,771	4,827	3,675	887	925	832	687	3,331	749	621	606
<i>Sales Infrastructure</i>					832	857	771	685	3,146	708	584	574
<i>Sales Other</i>					55	68	61	2	185	41	37	32
Adjusted EBITDA Infrastructure & Other	-40	96	124	54	16	30	-6	24	64	13	-11	31
<i>Adj. EBITDA Infrastructure</i>					66	108	68	33	275	61	38	54
<i>Adj. EBITDA Other</i>					-50	-78	-74	-9	-211	-48	-49	-23
EBIT	-375	-316	-641	-611	-59	-268	-107	-62	-496	-54	-90	-210
Adjusted EBIT	-362	-228	-224	-296	-49	-33	-74	-43	-199	-53	-80	-32
Capital expenditures	297	292	241	189	28	23	32	56	139	27	25	29
Employees	16,271	16,116	16,504	16,184	12,319	13,302	12,607	-	12,626	12,372	12,312	12,464

<sup>1</sup> Restated to reflect split of Technology & Infrastructure division into cross-site technology and site-specific infrastructure activities; smaller production sites, which often only serve one business line, have been allocated directly to the respective chemicals divisions

**Group Income Statement**

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3
Sales	12,199	14,955	18,488	15,267	3,796	3,930	3,832	3,599	15,157	3,777	3,499	3,391
Cost of sales	-8,865	-10,925	-14,257	-12,567	-2,795	-2,885	-2,804	-2,935	-11,419	-2,769	-2,568	-2,775
<b>Gross profit on sales</b>	<b>3,334</b>	<b>4,030</b>	<b>4,231</b>	<b>2,700</b>	<b>1,001</b>	<b>1,045</b>	<b>1,028</b>	<b>664</b>	<b>3,738</b>	<b>1,008</b>	<b>931</b>	<b>616</b>
Selling expenses	-1,501	-1,717	-2,035	-1,836	-473	-473	-468	-479	-1,894	-454	-434	-420
Research and development expenses	-433	-464	-460	-443	-111	-109	-106	-133	-459	-106	-105	-104
General administrative expenses	-531	-546	-554	-488	-129	-353	-128	-129	-740	-126	-125	-111
Other operating income & expenses	-65	-138	-252	-186	-38	-22	-7	-24	-89	-25	-33	-7
Result from investments recognized at equity	15	8	12	10	2	5	3	10	21	2	2	1
<b>Income before financial result and income taxes, cont. ops. = EBIT</b>	<b>819</b>	<b>1,173</b>	<b>942</b>	<b>-243</b>	<b>252</b>	<b>93</b>	<b>322</b>	<b>-91</b>	<b>577</b>	<b>299</b>	<b>236</b>	<b>-25</b>
Financial Result	-135	-88	-19	-108	-33	-31	-48	-30	-143	-29	-44	-52
<b>Income before income taxes, continuing operations</b>	<b>684</b>	<b>1,085</b>	<b>923</b>	<b>-351</b>	<b>219</b>	<b>62</b>	<b>274</b>	<b>-121</b>	<b>434</b>	<b>270</b>	<b>192</b>	<b>-77</b>
Income taxes	-181	-316	-369	-101	-59	-61	-47	-28	-194	-34	-68	-25
<b>Income after taxes, continuing operations</b>	<b>503</b>	<b>769</b>	<b>554</b>	<b>-452</b>	<b>160</b>	<b>1</b>	<b>227</b>	<b>-149</b>	<b>240</b>	<b>236</b>	<b>124</b>	<b>-102</b>
Income after taxes, discontinued operations	-24	-2	1	-	0	0	0	1	0	0	0	0
<b>Income after taxes</b>	<b>479</b>	<b>767</b>	<b>555</b>	<b>-452</b>	<b>160</b>	<b>1</b>	<b>227</b>	<b>-148</b>	<b>240</b>	<b>236</b>	<b>124</b>	<b>-102</b>
thereof attributable to non-controlling interests	14	21	15	13	4	6	4	4	18	3	4	4
<b>Shareholders of EVONIK Industries AG (net income)</b>	<b>465</b>	<b>746</b>	<b>540</b>	<b>-465</b>	<b>156</b>	<b>-5</b>	<b>223</b>	<b>-152</b>	<b>222</b>	<b>233</b>	<b>120</b>	<b>-106</b>
<b>EPS</b>	<b>1.00</b>	<b>1.60</b>	<b>1.16</b>	<b>-1.00</b>	<b>0.33</b>	<b>-0.01</b>	<b>0.48</b>	<b>-0.32</b>	<b>0.48</b>	<b>0.50</b>	<b>0.26</b>	<b>-0.23</b>

## Group Adjusted Income Statement

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3
<b>Sales</b>	<b>12,199</b>	<b>14,955</b>	<b>18,488</b>	<b>15,267</b>	<b>3,796</b>	<b>3,930</b>	<b>3,832</b>	<b>3,599</b>	<b>15,157</b>	<b>3,777</b>	<b>3,499</b>	<b>3,391</b>
<b>Adjusted EBITDA</b>	<b>1,906</b>	<b>2,383</b>	<b>2,490</b>	<b>1,656</b>	<b>522</b>	<b>578</b>	<b>577</b>	<b>388</b>	<b>2,065</b>	<b>560</b>	<b>509</b>	<b>448</b>
Adjusted depreciation and amortization	-1,016	-1,045	-1,140	-1,135	-256	-249	-255	-278	-1,038	-251	-259	-251
<b>Adjusted EBIT</b>	<b>890</b>	<b>1,338</b>	<b>1,350</b>	<b>521</b>	<b>266</b>	<b>329</b>	<b>322</b>	<b>110</b>	<b>1,027</b>	<b>309</b>	<b>250</b>	<b>197</b>
Adjusted net financial result	-146	-97	-19	-103	-33	-31	-48	-31	-143	-29	-44	-52
Adjusted depreciation and amortization on intar	149	162	169	153	35	35	34	40	144	34	32	33
<b>Adjusted income before income taxes, cont.</b>	<b>893</b>	<b>1,403</b>	<b>1,500</b>	<b>571</b>	<b>268</b>	<b>333</b>	<b>308</b>	<b>119</b>	<b>1,028</b>	<b>314</b>	<b>238</b>	<b>178</b>
Adjusted income taxes, continuing operations	-239	-396	-431	-188	-67	-93	-33	-40	-233	-36	-74	-46
<b>Adjusted income after taxes</b>	<b>654</b>	<b>1,007</b>	<b>1,069</b>	<b>383</b>	<b>201</b>	<b>240</b>	<b>275</b>	<b>79</b>	<b>795</b>	<b>278</b>	<b>164</b>	<b>132</b>
Adjusted non-controlling interest	-14	-21	-15	-13	-4	-6	-4	-4	-18	-3	-4	4
<b>Adjusted net income</b>	<b>640</b>	<b>986</b>	<b>1,054</b>	<b>370</b>	<b>197</b>	<b>234</b>	<b>271</b>	<b>74</b>	<b>777</b>	<b>275</b>	<b>160</b>	<b>128</b>
<b>Adjusted EPS</b>	<b>1.37</b>	<b>2.12</b>	<b>2.26</b>	<b>0.79</b>	<b>0.42</b>	<b>0.50</b>	<b>0.58</b>	<b>0.16</b>	<b>1.67</b>	<b>0.59</b>	<b>0.34</b>	<b>0.27</b>

## Adjustments

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3
Restructuring measures	-31	-32	-121	-64	-2	-228	-2	-173	-405	-12	7	-31
Acquisitions and divestments	-40	-29	40	-237	-11	-2	-18	-3	-34	-11	4	0
Other special items	0	-104	-327	-463	-1	-6	20	-24	-11	13	-25	-191
= Adjustments	-71	-165	-408	-764	-14	-236	0	-200	-450	-10	-14	-222

Adjustment categories changed as of December 31, 2023 to avoid overlaps between categories; prior year figures restated

**Group Balance Sheet**
**Assets**

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY	2025 Q1	2025 Q2	2025 Q3
Intangible assets	5,877	6,045	5,710	5,525	5,556	5,552	5,417	5,571	5,426	5,176	5,131
Property, plant and equipment	6,588	6,963	6,962	6,294	6,320	6,307	6,270	6,450	6,305	6,127	5,933
Right of use assets (capitalized leasing)	668	608	972	965	940	928	903	947	905	867	893
Investments recognized at equity	75	81	88	52	44	40	43	49	51	45	45
Trade accounts receivable										67	54
Financial assets	607	581	441	460	445	444	509	467	424	455	418
Deferred tax assets	2,004	1,755	890	642	672	678	677	664	629	624	659
Other income tax assets	13	16	19	20	21	22	21	25	24	22	22
Other non-financial assets	102	125	64	78	77	58	59	69	110	71	87
<b>Non-current assets</b>	<b>15,934</b>	<b>16,174</b>	<b>15,146</b>	<b>14,036</b>	<b>14,075</b>	<b>14,029</b>	<b>13,899</b>	<b>14,242</b>	<b>13,874</b>	<b>13,454</b>	<b>13,242</b>
Inventories	1,806	2,548	2,820	2,349		2,599	2,658	2,662	2,751	2,649	2,555
Other income tax assets	211	199	98	209	189	179	122	166	138	103	86
Trade accounts receivable	1,455	1,954	1,898	1,607		1,813	1,706	1,622	1,732	1,625	1,581
Other non-financial assets	231	382	517	373	407	462	433	381	440	377	363
Financial assets	697	571	610	381	371	342	284	216	574	467	266
Cash and cash equivalents	563	456	645	749	794	521	460	461	733	379	454
<b>Current assets</b>	<b>4,963</b>	<b>6,110</b>	<b>6,588</b>	<b>5,668</b>	<b>6,109</b>	<b>5,916</b>	<b>5,663</b>	<b>5,508</b>	<b>6,368</b>	<b>5,600</b>	<b>5,305</b>
Assets held for sale	0	0	76	236	264	261	0	0	0	0	0
<b>Current assets</b>	<b>4,963</b>	<b>6,110</b>	<b>6,664</b>	<b>5,904</b>	<b>6,373</b>	<b>6,177</b>	<b>5,663</b>	<b>5,508</b>	<b>6,368</b>	<b>5,600</b>	<b>5,305</b>
<b>Total assets</b>	<b>20,897</b>	<b>22,284</b>	<b>21,810</b>	<b>19,940</b>	<b>20,448</b>	<b>20,206</b>	<b>19,562</b>	<b>19,750</b>	<b>20,242</b>	<b>19,054</b>	<b>18,547</b>

**Liabilities**

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY	2025 Q1	2025 Q2	2025 Q3
Issued capital	466	466	466	466	466	466	466	466	466	466	466
Reserves	7,546	8,823	10,508	8,444	8,672	8,401	8,552	8,554	8,719	8,028	7,883
<b>Equity attributable to shareholders of Evonik Industries AG</b>	<b>8,012</b>	<b>9,289</b>	<b>10,974</b>	<b>8,910</b>	<b>9,138</b>	<b>8,867</b>	<b>9,018</b>	<b>9,020</b>	<b>9,185</b>	<b>8,494</b>	<b>8,349</b>
Equity attributable to non-controlling interests	87	83	82	76	78	71	77	80	82	65	64
<b>Total equity</b>	<b>8,099</b>	<b>9,372</b>	<b>11,056</b>	<b>8,986</b>	<b>9,216</b>	<b>8,938</b>	<b>9,095</b>	<b>9,100</b>	<b>9,267</b>	<b>8,559</b>	<b>8,413</b>
Provisions for pensions and other post-employment benefits	4,618	3,766	1,359	1,858	1,828	1,575	1,564	1,662	1,449	1,383	1,387
Other provisions	715	657	542	517	520	688	681	734	734	651	667
Deferred tax liabilities	586	628	661	608	613	630	614	638	633	625	629
Other income tax liabilities	275	195	246	268	273	271	266	254	258	268	246
Financial liabilities	3,564	3,531	4,117	3,502	3,519	3,485	3,135	3,162	3,629	3,586	3,663
Other payables	114	143	182	153	139	129	130	141	97	109	95
<b>Non-current liabilities</b>	<b>9,872</b>	<b>8,920</b>	<b>7,107</b>	<b>6,906</b>	<b>6,892</b>	<b>6,778</b>	<b>6,390</b>	<b>6,591</b>	<b>6,800</b>	<b>6,622</b>	<b>6,687</b>
Other provisions	744	892	732	606	681	711	833	923	955	695	724
Other income tax liabilities	136	211	189	124	152	151	111	87	86	63	59
Financial liabilities	434	477	429	1,153	1,130	1,205	1,083	1,034	941	1,215	830
Trade accounts payable	1,273	2,022	1,735	1,521	1,675	1,682	1,511	1,600	1,702	1,440	1,359
Other payables	339	390	501	457	485	535	539	415	491	460	475
<b>Current liabilities</b>	<b>2,926</b>	<b>3,992</b>	<b>3,586</b>	<b>3,861</b>	<b>4,123</b>	<b>4,284</b>	<b>4,077</b>	<b>4,059</b>	<b>4,175</b>	<b>3,873</b>	<b>3,447</b>
Liabilities associated with assets held for sale	0	0	61	187	217	206	0	0	0	0	0
<b>Current liabilities</b>	<b>2,926</b>	<b>3,992</b>	<b>3,647</b>	<b>4,048</b>	<b>4,340</b>	<b>4,490</b>	<b>4,077</b>	<b>4,059</b>	<b>4,175</b>	<b>3,873</b>	<b>3,447</b>
<b>Total equity and liabilities</b>	<b>20,897</b>	<b>22,284</b>	<b>21,810</b>	<b>19,940</b>	<b>20,448</b>	<b>20,206</b>	<b>19,562</b>	<b>19,750</b>	<b>20,242</b>	<b>19,054</b>	<b>18,547</b>

**Group Cash Flow Statement**

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3
Income before financial result and income taxes, continuing operations = EBIT	819	1,173	942	-243	252	93	321	-90	577	299	236	-25
Depreciation, amortization, impairment losses/reversal of impairment losses on n	1,018	1,073	1,568	1,841	265	250	234	368	1,117	240	260	428
Result from investments recognized at equity	-15	-8	-12	-10	-2	-6	-3	-10	-21	-2	-3	0
Gains/losses on disposal of non current assets	-10	43	-50	-1	-3	-1	21	5	22	15	4	5
Change in inventories	70	-675	-270	310	-218	-34	-99	54	-297	-140	7	94
Change in trade accounts receivable	54	-449	42	105	-180	-35	118	118	21	-143	-16	52
Change in trade accounts payable and current advance payments received from	-30	680	-257	-157	261	-11	-180	4	74	185	-228	-67
Change in provisions for pensions and other post-employment benefits	-14	83	-19	-55	-31	-13	0	-4	-48	-4	-13	-28
Change in other provisions	-133	207	-149	-141	76	192	126	141	535	37	-341	40
Change in miscellaneous assets/liabilities	33	-23	10	152	-28	-23	16	-45	-81	-100	78	7
Cash inflows from dividends	27	19	19	25	-	20	1	6	27	0	19	0
Tax payments relating to carve-out of the methacrylates business	-	-	-	-	-	-	-	-	-	-	-	-
Cash inflows/outflows for income taxes	-83	-308	-174	-232	-14	-72	-18	-109	-213	-2	-38	-25
<b>Cash flow from operating activities, continuing operations</b>	<b>1,736</b>	<b>1,815</b>	<b>1,650</b>	<b>1,594</b>	<b>378</b>	<b>360</b>	<b>537</b>	<b>438</b>	<b>1,713</b>	<b>385</b>	<b>-35</b>	<b>481</b>
Cash flow from operating activities, discontinued operations	-9	0	0	0	0	0	0	0	0	0	0	0
<b>Cash flow from operating activities</b>	<b>1,727</b>	<b>1,815</b>	<b>1,650</b>	<b>1,594</b>	<b>378</b>	<b>360</b>	<b>537</b>	<b>438</b>	<b>1,713</b>	<b>385</b>	<b>-35</b>	<b>481</b>
Cash outflows for investments in intangible assets, property, plant and equipment	-956	-865	-865	-793	-251	-143	-180	-266	-840	-190	-176	-181
Cash outflows for investments in shareholdings	-474	-85	-27	-76	-3	-4	-14	0	-15	0	0	-1
Cash outflows for loss from divestments of shareholdings	-	-145	97	-32	-13	0	0	0	-13	0	-1	0
Cash outflows from divestments of businesses and other shareholdings	-	-21	-	-5	0	0	0	0	0	0	0	0
Cash inflows from divestments of intangible assets, property, plant and equipmen	45	9	5	15	16	3	-5	7	21	8	0	1
Cash inflows for loss from divestments of shareholdings	65	2	-	43	-	3	17	-4	16	3	6	0
Cash inflows for investments in shareholdings	-	-	-	2	-	-	-	0	0	2	1	0
Cash inflows/outflows relating to securities, deposits and loans	720	23	-3	161	-13	14	85	52	137	-352	199	164
Cash inflows from interest	30	12	16	32	12	8	11	6	37	20	7	6
<b>Cash flow from investing activities, continuing operations</b>	<b>-570</b>	<b>-1,070</b>	<b>-777</b>	<b>-653</b>	<b>-252</b>	<b>-119</b>	<b>-86</b>	<b>-205</b>	<b>-663</b>	<b>-509</b>	<b>36</b>	<b>-11</b>
Cash flow from investing activities, discontinued operations	0	0	0	0	0	0	0	0	0	0	0	0
<b>Cash flow from investing activities</b>	<b>-570</b>	<b>-1,070</b>	<b>-777</b>	<b>-653</b>	<b>-252</b>	<b>-119</b>	<b>-86</b>	<b>-205</b>	<b>-663</b>	<b>-509</b>	<b>36</b>	<b>-11</b>
Cash inflows/outflows relating to capital contributions	2	0	0	0	0	0	0	0	0	1	3	0
Cash outflows for dividends to shareholders of Evonik Industries AG	-536	-536	-545	-545	0	-545	0	0	-545	-	-545	0
Cash outflows for dividends to non-controlling interests	-16	-21	-13	-10	-4	-12	0	-4	-20	-1	-4	-4
Cash infows/outflows from changes in ownership interests in subsidiaries without	0	0	-5	-	-	0	0	-	0	0	-19	0
Cash outflows for the purchase of treasury shares	-16	-15	-16	-16	-12	0	0	0	-12	0	-1	0
Cash inflows from the sale of treasury shares	12	12	12	12	-	9	0	0	9	0	1	0
Cash inflows from the addition of financial liabilities	1,039	655	1,649	716	19	134	487	68	708	521	308	921
Cash outflows for repayment of financial liabilities	-2,156	-948	-1,577	-893	-82	-65	-946	-261	-1,354	-107	-79	-1,252
Cash inflows/outflows in connection with financial transactions	14	91	-104	12	11	-16	7	-8	-7	0	5	0
Cash outflows for interest	-77	-94	-73	-99	-17	-15	-52	-25	-109	-14	-12	-53
<b>Cash flow from financing activities, continuing operations</b>	<b>-1,734</b>	<b>-856</b>	<b>-672</b>	<b>-823</b>	<b>-85</b>	<b>-510</b>	<b>-504</b>	<b>-230</b>	<b>-1,330</b>	<b>400</b>	<b>-343</b>	<b>-388</b>
Cash flow from financing activities, discontinued operations	0	0	0	0	0	0	0	0	0	0	0	0
<b>Cash flow from financing activities</b>	<b>-1,734</b>	<b>-856</b>	<b>-672</b>	<b>-823</b>	<b>-85</b>	<b>-510</b>	<b>-504</b>	<b>-230</b>	<b>-1,330</b>	<b>400</b>	<b>-343</b>	<b>-388</b>
<b>Change in cash and cash equivalents</b>	<b>-577</b>	<b>-111</b>	<b>201</b>	<b>118</b>	<b>41</b>	<b>-269</b>	<b>-53</b>	<b>1</b>	<b>-280</b>	<b>276</b>	<b>-342</b>	<b>82</b>
<b>Cash and cash equivalents as of beginning of period</b>	<b>1,165</b>	<b>563</b>	<b>456</b>	<b>645</b>	<b>749</b>	<b>794</b>	<b>519</b>	<b>460</b>	<b>749</b>	<b>460</b>	<b>735</b>	<b>379</b>
Change in cash and cash equivalents	-577	-111	201	118	41	-269	-53	3	-280	276	-342	82
Changes in exchange rates and other changes in cash and cash equivalents	-25	4	-12	-14	4	-4	-7	-2	-8	-3	-14	-7
<b>Cash and cash equivalents as of end of period</b>	<b>563</b>	<b>456</b>	<b>645</b>	<b>749</b>	<b>794</b>	<b>521</b>	<b>459</b>	<b>461</b>	<b>461</b>	<b>733</b>	<b>379</b>	<b>454</b>
Cash and cash equivalents included in assets held for sale	0	0	0	0	0	0	0	0	0	0	0	0
<b>Cash and cash equivalents as on the balance sheet as of end of period</b>	<b>563</b>	<b>456</b>	<b>645</b>	<b>749</b>	<b>794</b>	<b>521</b>	<b>459</b>	<b>461</b>	<b>461</b>	<b>733</b>	<b>379</b>	<b>454</b>

**Group Net Financial Position**

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY	2025 Q1	2025 Q2	2025 Q3
Non-current financial liabilities	-3,564	-3,527	-4,074	-4,064	-4,118	-3,335	-3,320	-3,302	-3,288	-2,955	-2,961	-3,429	-3,393	-3,482
Current financial liabilities	-368	-232	-243	-264	-711	-1,160	-1,006	-979	-1,105	-971	-883	-845	-1,136	-771
<b>Financial debt</b>	<b>-3,932</b>	<b>-3,759</b>	<b>-4,317</b>	<b>-4,328</b>	<b>-4,829</b>	<b>-4,495</b>	<b>-4,326</b>	<b>-4,281</b>	<b>-4,393</b>	<b>-3,926</b>	<b>-3,844</b>	<b>-4,274</b>	<b>-4,529</b>	<b>-4,253</b>
- Cash and cash equivalents	563	456	645	634	398	588	749	794	521	460	461	733	379	454
- Current securities	466	446	413	434	313	165	261	269	259	176	128	482	285	121
- Other financial assets	17	0	2	2	2	2	6	6	2	4	2	1	1	1
<b>Financial assets</b>	<b>1,046</b>	<b>902</b>	<b>1,060</b>	<b>1,070</b>	<b>713</b>	<b>755</b>	<b>1,016</b>	<b>1,069</b>	<b>782</b>	<b>640</b>	<b>591</b>	<b>1,216</b>	<b>665</b>	<b>576</b>
<b>Net financial debt/cash as stated on the balance sheet</b>	<b>-2,886</b>	<b>-2,857</b>	<b>-3,257</b>	<b>-3,258</b>	<b>-4,116</b>	<b>-3,740</b>	<b>-3,310</b>	<b>-3,212</b>	<b>-3,611</b>	<b>-3,286</b>	<b>-3,253</b>	<b>-3,058</b>	<b>-3,864</b>	<b>-3,677</b>
<b>Net financial debt/cash, discontinued operations</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Net financial debt/cash including discontinued operations</b>	<b>-2,886</b>	<b>-2,857</b>	<b>-3,257</b>	<b>-3,258</b>	<b>-4,116</b>	<b>-3,740</b>	<b>-3,310</b>	<b>-3,212</b>	<b>-3,611</b>	<b>-3,286</b>	<b>-3,253</b>	<b>-3,058</b>	<b>-3,864</b>	<b>-3,677</b>

## Financial KPI Definitions

<b>Adjusted EBIT</b>	Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets.
<b>Adjusted EBITDA</b>	Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors.
<b>Adjusted net income</b>	We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items.
<b>Adjustments</b>	Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business.
<b>Free Cash Flow</b>	The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment.
<b>ROCE</b>	The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period.

## ESG KPI Definitions

<b>Value added in € million</b>	We use an impact valuation to regularly measure and analyze the direct and indirect impacts from an economic, ecological, and social perspective. This supplements our established analytical approaches. We anticipate that this will allow early identification of potential future opportunities and risks, make our business model more resilient, and improve understanding of the long-term value that our business activities create for society. We aim to assign a monetary value to individual indicators such as continuing development of employees, employment impacts, and global warming so they can be compared. Most of the factors used for this are publicly available.
<b>Sales share with "Next Generation Solutions"</b>	Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA) For more information please see Evonik website: Responsibility - Value Chain & Products - Sustainability Analysis
<b>Internal Investigations</b>	Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included.
<b>Disciplinary Measures</b>	Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated.
<b>Raw Material Suppliers Covered by TFS Assessments</b>	This number indicates how many raw material suppliers have been covered by TFS assessments in that year. The chemical industry set up the Together for Sustainability (TFS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative.
<b>Greenhouse Gas Emissions</b>	Scope 1: Evonik's direct energy and process-related emissions; Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach); Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, energy requirements for offices and emissions from the disposal and recycling of products sold.
<b>Early Employee Turnover</b>	Turnover of newly hired employees within the first year of employment
<b>Management circles/ levels</b>	Management circle 1 = executive functions, i.e., top management functions in the Evonik Group Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions Management circle 3 = further management functions
<b>Occupational Health Performance Index</b>	This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually.
<b>Specific water intake</b> <small>in m<sup>3</sup> freshwater per metric ton production</small>	Freshwater usage in relation to production.
<b>Total water intake</b>	Evonik's consumption of freshwater is the total of drinking water, groundwater, surface water, and recycled water. Total water intake is the sum of total freshwater and salt water (sea water).